CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder
Neuropsychopharmacology, 2026
Paslawski W., Doyon D., Ekman C., Yngwe H., Mamula D., Zareba-Paslawska J., Beckman M., Xu Z., Hökfelt T., Tiger M., Lundberg J., Svenningsson P.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology | Pathophysiology | CSF |  Olink Target 96 |
Abstract
Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.